{"pmid":32442561,"title":"COVID-19 in Liver Transplant Recipients: An Initial Experience from the U.S. Epicenter.","text":["COVID-19 in Liver Transplant Recipients: An Initial Experience from the U.S. Epicenter.","Gastroenterology","Lee, Brian T","Perumalswami, Ponni V","Im, Gene Y","Florman, Sander","Schiano, Thomas D","32442561"],"journal":"Gastroenterology","authors":["Lee, Brian T","Perumalswami, Ponni V","Im, Gene Y","Florman, Sander","Schiano, Thomas D"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32442561","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1053/j.gastro.2020.05.050","keywords":["coronavirus","immunosuppression","liver transplantation","outcomes"],"topics":["Treatment"],"weight":1,"_version_":1667535119565455361,"score":9.490897,"similar":[{"pmid":32277387,"pmcid":"PMC7146012","title":"Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation.","text":["Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation.","Annually, around 850 liver transplantation is performed in Beijing, China. Recently, the new coronavirus pneumonia (COVID-19) caused by 2019 novel coronavirus (2019-nCoV) has affected nearly 200 countries worldwide. 2019-nCov can cause severe lung disease, multiple-organ damage, and significant mortalities. Liver transplant recipients, because of long-term oral immunosuppressant effects, may be more susceptible to 2019-nCoV infection and have a worse prognosis than the general population. It is urgent to set up guidelines for the prevention, diagnosis, and treatment of COVID-19 in liver transplant recipients. In this article, we reviewed the clinical aspects of 2019-nCoV infection, characteristics of liver transplant recipients, immunosuppressant usage, and potential drug interactions to provide recommendations to clinical staff managing liver transplant recipients during the COVID-19 epidemic.","Hepatol Int","Liu, Hongling","He, Xi","Wang, Yudong","Zhou, Shuangnan","Zhang, Dali","Zhu, Jiye","He, Qiang","Zhu, Zhijun","Li, Guangming","Sun, Libo","Wang, Jianli","Cheng, Gregory","Liu, Zhenwen","Lau, George","32277387"],"abstract":["Annually, around 850 liver transplantation is performed in Beijing, China. Recently, the new coronavirus pneumonia (COVID-19) caused by 2019 novel coronavirus (2019-nCoV) has affected nearly 200 countries worldwide. 2019-nCov can cause severe lung disease, multiple-organ damage, and significant mortalities. Liver transplant recipients, because of long-term oral immunosuppressant effects, may be more susceptible to 2019-nCoV infection and have a worse prognosis than the general population. It is urgent to set up guidelines for the prevention, diagnosis, and treatment of COVID-19 in liver transplant recipients. In this article, we reviewed the clinical aspects of 2019-nCoV infection, characteristics of liver transplant recipients, immunosuppressant usage, and potential drug interactions to provide recommendations to clinical staff managing liver transplant recipients during the COVID-19 epidemic."],"journal":"Hepatol Int","authors":["Liu, Hongling","He, Xi","Wang, Yudong","Zhou, Shuangnan","Zhang, Dali","Zhu, Jiye","He, Qiang","Zhu, Zhijun","Li, Guangming","Sun, Libo","Wang, Jianli","Cheng, Gregory","Liu, Zhenwen","Lau, George"],"date":"2020-04-12T11:00:00Z","year":2020,"_id":"32277387","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1007/s12072-020-10043-z","keywords":["2019-ncov","covid-19","liver transplantation","management"],"locations":["Beijing","China","Beijing"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Prevention","Diagnosis","Treatment"],"weight":1,"_version_":1666138491597094912,"score":68.20611},{"pmid":32439237,"title":"Liver transplantation in the era of COVID-19.","text":["Liver transplantation in the era of COVID-19.","Liver transplantation is considered the ultimate solution for patients with end-stage chronic liver disease or acute liver failure. Patients with liver transplant need special care starting from preoperative preparation, surgical intervention ending with postoperative care. Transplanted patients have to receive immunosuppressive therapy to prevent rejection. Such a state of immune suppression could predispose to different types of infections in liver transplant recipients. Currently, the world is suffering a pandemic caused by a new strain of the coronavirus family called COVID-19. Certain infection control precautions are needed to protect immunocompromised and vulnerable patients, including liver transplant candidates and recipients from acquiring COVID-19 infection. Restricting non-transplant elective surgical procedures, managing transplant patients in separate outpatient clinics, and in-patient wards can prevent transmission of infection both to patients and healthcare workers. Telemedicine can help in the triage of patients to screen for symptoms of COVID-19 before their regular appointment. Management of immunosuppressive therapy and drug-drug interactions in liver transplant recipients infected with COVID-19 should be cautiously practiced to prevent rejection and effectively treat the underlying infection. In this report, we are trying to summarize available evidence about different aspects of the management of liver transplant candidates and recipients in the era of COVID-19.","Arab J Gastroenterol","El Kassas, Mohamed","Alboraie, Mohamed","Al Balakosy, Amira","Abdeen, Nermeen","Afify, Shimaa","Abdalgaber, Mohammad","Sherief, Ahmed F","Madkour, Ahmad","Abdellah Ahmed, Mohamed","Eltabbakh, Mohamed","Salaheldin, Mohamed","Wifi, Mohamed-Naguib","32439237"],"abstract":["Liver transplantation is considered the ultimate solution for patients with end-stage chronic liver disease or acute liver failure. Patients with liver transplant need special care starting from preoperative preparation, surgical intervention ending with postoperative care. Transplanted patients have to receive immunosuppressive therapy to prevent rejection. Such a state of immune suppression could predispose to different types of infections in liver transplant recipients. Currently, the world is suffering a pandemic caused by a new strain of the coronavirus family called COVID-19. Certain infection control precautions are needed to protect immunocompromised and vulnerable patients, including liver transplant candidates and recipients from acquiring COVID-19 infection. Restricting non-transplant elective surgical procedures, managing transplant patients in separate outpatient clinics, and in-patient wards can prevent transmission of infection both to patients and healthcare workers. Telemedicine can help in the triage of patients to screen for symptoms of COVID-19 before their regular appointment. Management of immunosuppressive therapy and drug-drug interactions in liver transplant recipients infected with COVID-19 should be cautiously practiced to prevent rejection and effectively treat the underlying infection. In this report, we are trying to summarize available evidence about different aspects of the management of liver transplant candidates and recipients in the era of COVID-19."],"journal":"Arab J Gastroenterol","authors":["El Kassas, Mohamed","Alboraie, Mohamed","Al Balakosy, Amira","Abdeen, Nermeen","Afify, Shimaa","Abdalgaber, Mohammad","Sherief, Ahmed F","Madkour, Ahmad","Abdellah Ahmed, Mohamed","Eltabbakh, Mohamed","Salaheldin, Mohamed","Wifi, Mohamed-Naguib"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32439237","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.ajg.2020.04.019","keywords":["covid-19","coronavirus","liver transplantation"],"topics":["Prevention"],"weight":1,"_version_":1667523504770121729,"score":65.007034},{"pmid":32330343,"title":"COVID-19 in Solid Organ Transplant Recipients: Initial Report from the US Epicenter.","text":["COVID-19 in Solid Organ Transplant Recipients: Initial Report from the US Epicenter.","Solid organ transplant recipients may be at a high risk for SARS-CoV2 infection and poor associated outcomes. We herein report our initial experience with solid organ transplant recipients with SARS-CoV2 infection at two centers during the first 3 weeks of the outbreak in New York City. Baseline characteristics, clinical presentation, antiviral and immunosuppressive management were compared between patients with mild/moderate and severe disease (defined as ICU admission, intubation or death). 90 patients were analyzed with a median age of 57 years. 46 were kidney recipients, 17 lung, 13 liver, 9 heart and 5 dual-organ transplants. The most common presenting symptoms were fever (70%), cough (59%) and dyspnea (43%). 22 (24%) had mild, 41 (46%) moderate and 27 (30%) severe disease. Among the 68 hospitalized patients, 12% required non-rebreather and 35% required intubation. 91% received hydroxychloroquine, 66% azithromycin, 3% remdesivir, 21% tocilizumab and 24% bolus steroids. Sixteen patients died (18% overall, 24% of hospitalized, 52% of ICU) and 37 (54%) were discharged. In this initial cohort, transplant recipients with COVID-19 appear to have more severe outcomes, although testing limitations likely led to undercounting of mild/asymptomatic cases. As this outbreak unfolds, COVID-19 has the potential to severely impact solid organ transplant recipients.","Am J Transplant","Pereira, Marcus R","Mohan, Sumit","Cohen, David J","Husain, S Ali","Dube, Geoffrey K","Ratner, Lloyd E","Arcasoy, Selim","Aversa, Meghan M","Benvenuto, Luke J","Dadhani, Darshana","Kapur, Sandip","Dove, Lorna M","Brown, Robert S","Rosenblatt, Russell E","Samstein, Benjamin","Uriel, Nir","Farr, Maryjane A","Satlin, Michael","Small, Cathy B","Walsh, Thomas","Kodiyanplakkal, Rosy Priya","Miko, Benjamin A","Aaron, Justin G","Tsapepas, Demetra S","Emond, Jean C","Verna, Elizabeth C","32330343"],"abstract":["Solid organ transplant recipients may be at a high risk for SARS-CoV2 infection and poor associated outcomes. We herein report our initial experience with solid organ transplant recipients with SARS-CoV2 infection at two centers during the first 3 weeks of the outbreak in New York City. Baseline characteristics, clinical presentation, antiviral and immunosuppressive management were compared between patients with mild/moderate and severe disease (defined as ICU admission, intubation or death). 90 patients were analyzed with a median age of 57 years. 46 were kidney recipients, 17 lung, 13 liver, 9 heart and 5 dual-organ transplants. The most common presenting symptoms were fever (70%), cough (59%) and dyspnea (43%). 22 (24%) had mild, 41 (46%) moderate and 27 (30%) severe disease. Among the 68 hospitalized patients, 12% required non-rebreather and 35% required intubation. 91% received hydroxychloroquine, 66% azithromycin, 3% remdesivir, 21% tocilizumab and 24% bolus steroids. Sixteen patients died (18% overall, 24% of hospitalized, 52% of ICU) and 37 (54%) were discharged. In this initial cohort, transplant recipients with COVID-19 appear to have more severe outcomes, although testing limitations likely led to undercounting of mild/asymptomatic cases. As this outbreak unfolds, COVID-19 has the potential to severely impact solid organ transplant recipients."],"journal":"Am J Transplant","authors":["Pereira, Marcus R","Mohan, Sumit","Cohen, David J","Husain, S Ali","Dube, Geoffrey K","Ratner, Lloyd E","Arcasoy, Selim","Aversa, Meghan M","Benvenuto, Luke J","Dadhani, Darshana","Kapur, Sandip","Dove, Lorna M","Brown, Robert S","Rosenblatt, Russell E","Samstein, Benjamin","Uriel, Nir","Farr, Maryjane A","Satlin, Michael","Small, Cathy B","Walsh, Thomas","Kodiyanplakkal, Rosy Priya","Miko, Benjamin A","Aaron, Justin G","Tsapepas, Demetra S","Emond, Jean C","Verna, Elizabeth C"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32330343","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1111/ajt.15941","locations":["New York"],"countries":["United States"],"countries_codes":["USA|United States"],"e_drugs":["Hydroxychloroquine","remdesivir","Azithromycin","tocilizumab","Steroids"],"topics":["Treatment"],"weight":1,"_version_":1666138494683054081,"score":61.68216},{"pmid":32500942,"title":"Outcome of COVID-19 in Liver Transplant Recipients: a Preliminary Report from Northwestern Italy.","text":["Outcome of COVID-19 in Liver Transplant Recipients: a Preliminary Report from Northwestern Italy.","Covid-19 pandemic is deeply affecting transplant activity worldwide. It is unclear whether solid organ transplant recipients are at increased risk of developing severe complications and how they should be managed, also concerning immunosuppression. This is a report about the course and management of SARS-CoV-2 infection in liver transplant recipients from a single center in Northwestern Italy in the period March-April 2020. Three patients who were treated at our Institution are reported in details, whereas summary data are provided for those managed at peripheral Hospitals. Presentation varied from asymptomatic to rapidly progressive respiratory failure due to bilateral interstitial pneumonia. Accordingly, treatment and changes to immunosuppression were adapted to the severity of the disease. Overall mortality was 20%, whereas Covid-related mortality was 10%. Two cases of prolonged (> 2 months) viral carriage were observed in two asymptomatic patients who contracted the infection in the early course after transplant. Besides depicting Covid-19 course and possible treatment scenarios in liver transplant patients, these cases are discussed in relation to the changes in our practice prompted by Covid-19 epidemic, with potential implications for other transplant programs.","Transpl Infect Dis","Patrono, Damiano","Lupo, Francesco","Canta, Francesca","Mazza, Elena","Mirabella, Stefano","Corcione, Silvia","Tandoi, Francesco","De Rosa, Francesco Giuseppe","Romagnoli, Renato","32500942"],"abstract":["Covid-19 pandemic is deeply affecting transplant activity worldwide. It is unclear whether solid organ transplant recipients are at increased risk of developing severe complications and how they should be managed, also concerning immunosuppression. This is a report about the course and management of SARS-CoV-2 infection in liver transplant recipients from a single center in Northwestern Italy in the period March-April 2020. Three patients who were treated at our Institution are reported in details, whereas summary data are provided for those managed at peripheral Hospitals. Presentation varied from asymptomatic to rapidly progressive respiratory failure due to bilateral interstitial pneumonia. Accordingly, treatment and changes to immunosuppression were adapted to the severity of the disease. Overall mortality was 20%, whereas Covid-related mortality was 10%. Two cases of prolonged (> 2 months) viral carriage were observed in two asymptomatic patients who contracted the infection in the early course after transplant. Besides depicting Covid-19 course and possible treatment scenarios in liver transplant patients, these cases are discussed in relation to the changes in our practice prompted by Covid-19 epidemic, with potential implications for other transplant programs."],"journal":"Transpl Infect Dis","authors":["Patrono, Damiano","Lupo, Francesco","Canta, Francesca","Mazza, Elena","Mirabella, Stefano","Corcione, Silvia","Tandoi, Francesco","De Rosa, Francesco Giuseppe","Romagnoli, Renato"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32500942","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/tid.13353","keywords":["covid-19","early infection","immunosuppression","viral carriage"],"topics":["Case Report"],"weight":1,"_version_":1668890966355869697,"score":58.543465},{"pmid":32400013,"title":"A case of coronavirus disease 2019-infected liver transplant donor.","text":["A case of coronavirus disease 2019-infected liver transplant donor.","Coronavirus disease 2019 (COVID-19) is a novel infectious disease that continues to spread on a global scale. There has been growing concern about donor-derived transmissions of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Herein, we present the case of a patient who underwent ABO-incompatible living donor liver transplantation without knowing that the liver donor was infected with COVID-19 during the donation procedure. In this case, the donor-derived transmission to the recipient was not identified, and the liver donor was found to be recovering from a COVID-19 infection. The donor-derived transmission was not identified.","Am J Transplant","Hong, Hyo-Lim","Kim, Sung-Han","Choi, Dong Lak","Kwon, Hyun Hee","32400013"],"abstract":["Coronavirus disease 2019 (COVID-19) is a novel infectious disease that continues to spread on a global scale. There has been growing concern about donor-derived transmissions of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Herein, we present the case of a patient who underwent ABO-incompatible living donor liver transplantation without knowing that the liver donor was infected with COVID-19 during the donation procedure. In this case, the donor-derived transmission to the recipient was not identified, and the liver donor was found to be recovering from a COVID-19 infection. The donor-derived transmission was not identified."],"journal":"Am J Transplant","authors":["Hong, Hyo-Lim","Kim, Sung-Han","Choi, Dong Lak","Kwon, Hyun Hee"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32400013","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1111/ajt.15997","keywords":["covid-19","liver transplantation"],"topics":["Case Report"],"weight":1,"_version_":1666865855040847872,"score":57.500725}]}